Skip to main content

Advertisement

Table 1 Baseline characteristics and anti-citrullinated protein antibody (ACPA) reactivities in subgroups of patients with rheumatoid arthritis (RA) and controls

From: The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy

  All RA
n = 217
Anti-CCP+
n = 178
Anti-CCP-
n = 39
RF+
n = 154
RF-
n = 63
Anti-CCP+/RF+
n = 147
Anti-CCP-/RF-
n = 32
Controls
n = 94
Age, yearsa 51.5 (13.6) 50.8 (13.2) 55.0 (14.9) 51.9 (13.3) 50.8 (14.2) 51.7 (13.6) 55.0 (16.1) 52.1 (9.2)
Femaleb 131 (60) 109 (61) 22 (56) 91 (59) 40 (63) 86 (59) 17 (53) 57 (61)
Ever-smokerb 148 (68) 122 (69) 26 (67) 109 (71) 39 (62) 103 (70) 20 (62) 60 (64)
DASa 3.5 (1.2) 3.4 (1.1) 4.0 (1.3) 3.5 (1.2) 3.5 (1.2) 3.42 (1.1) 3.9 (1.2) NA
DAS28a 4.4 (1.2) 4.4 (1.2) 4.7 (1.2) 4.5 (1.2) 4.2 (1.3) 4.5 (1.1) 4.5 (1.1) NA
vdHSS totalc 4.0 [1.5, 8.0] 4.0 [1.5, 7.9] 4.5 [2.0, 10] 4.5 [2.0, 8.0] 3.5 [1.5, 10] 4.5 [2.0, 8.0] 5.5 [1.8, 12.8] NA
vdHSS erosionc 3.0 [1, 4.5] 3.0 [1, 4.5] 3.0 [1.0, 5.5] 3.0 [1.5, 4.5] 3.0 [1.0, 5.5] 3.0 [1.0, 4.5] 3.0 [1.0, 6.3] NA
vdHSS JSNc 1.0 [0.0, 3.0] 1.0 [0.0, 3.0] 1.5 [0.0, 5.0] 1.0 [0.0, 3.0] 1.0 [0.0, 3.0] 1.0 [0.0, 3.0] 1.5 [0.0, 6.5] NA
Ultrasound grey scalec 18 [10, 28] 16 [9, 24] 33 [20, 51] 17 [10, 26] 21 [12, 36] 16 [9, 25] 33 [21, 52] NA
Ultrasound power Dopplerc 7 [3, 14] 6 [2, 12] 14 [6, 28] 6 [2, 13] 8 [3, 15] 6 [2, 12] 13 [6, 29] NA
Number of ACPA reactivitiesc 9 [4, 12] 10 [7, 12] 0 [0, 1] 10 [7, 12] 2 [0, 10] 10 [7, 12] 0 [0, 1] 0 [0, 0]
ACPA reactivity status, n (%)
 Fibβ 60-74cit 162 (75) 160 (90) 2 (5) 136 (88) 26 (41) 134 (91) 0 (0) 0 (0)
 Vim 60-75cit 159 (73) 152 (85) 7 (18) 130 (84) 29 (46) 128 (87) 5 (16) 5 (5)
 H4 31-50cit 145 (67) 142 (80) 3 (8) 119 (77) 26 (41) 118 (80) 2 (6) 1 (1)
 CEP-1 140 (65) 137 (77) 3 (8) 117 (76) 23 (37) 115 (78) 1 (3) 1 (1)
 Fil 307-324cit 136 (63) 134 (75) 2 (5) 113 (73) 23 (37) 112 (76) 1 (3) 0 (0)
 Fibα 573cit 123 (57) 121 (68) 2 (5) 99 (64) 24 (38) 99 (67) 2 (6) 0 (0)
 Fibβ 36-52cit 117 (54) 116 (65) 1 (3) 96 (62) 21 (33) 96 (65) 1 (3) 2 (2)
 H3 1-30cit 107 (49) 106 (60) 1 (3) 93 (60) 14 (22) 92 (63) 0 (0) 0 (0)
 H4 14-34cit 105 (48) 103 (58) 2 (5) 90 (58) 15 (24) 88 (60) 0 (0) 3 (3)
 H3 21-44cit 96 (44) 94 (53) 2 (5) 80 (52) 16 (25) 79 (54) 1 (3) 1 (1)
 Fibα 621-635cit 93 (43) 92 (52) 1 (3) 78 (51) 15 (24) 77 (52) 0 (0) 1 (1)
 Vim 2-17cit 88 (41) 87 (49) 1 (3) 80 (52) 8 (13) 79 (54) 0 (0) 0 (0)
 Fibα 36-50cit 79 (36) 79 (44) 0 (0) 67 (44) 12 (19) 67 (46) 0 (0) 0 (0)
 Fibα 591cit 69 (32) 66 (37) 3 (8) 56 (36) 13 (21) 55 (37) 2 (6) 1 (1)
 Fibβ 74cit 66 (30) 60 (34) 6 (15) 54 (35) 12 (19) 51 (35) 3 (9) 3 (3)
 Fibβ 72cit 27 (12) 24 (13) 3 (8) 21 (14) 6 (1) 20 (14) 2 (6) 2 (2)
  1. Abbreviations: RA rheumatoid arthritis; anti-CCP anti-cyclic citrullinated peptide, RF rheumatoid factor, DAS Disease Activity Score, vdHSS van der Heijde modified Sharp score, JSN joint space narrowing, ACPA anti-citrullinated protein antibody, Fib fibrinogen, cit citrullinated, Vim vimentin, H histone, CEP-1 citrullinated enolase peptide-1, Fil filaggrin; numbers referring to amino acid sequence, NA not applicable
  2. aMean (SD)
  3. bNumber (percentage)
  4. cMedian [25, 75 percentile]